Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tyra BiosciencesTYRA -3.48%28 Equity-to-Asset is 0.94 as of Mar. 2026, which is 1% below its 10-year median of 0.95. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Tyra Biosciences ranks better than 91.81% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Tyra Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $387.58 Mil. Tyra Biosciences's Total Assets for the quarter that ended in Mar. 2026 was $412.04 Mil.
The historical rank and industry rank for Tyra Biosciences's Equity-to-Asset or its related term are showing as below:
TYRA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -8.98 Med: 0.95 Max: 0.98
Current: 0.94
During the past 7 years, the highest Equity to Asset Ratio of Tyra Biosciences was 0.98. The lowest was -8.98. And the median was 0.95.
TYRA's Equity-to-Asset is ranked better than 91.81% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs TYRA: 0.94
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Tyra Biosciences Equity-to-Asset Related Terms
Tyra Biosciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Tyra Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYRA vs STOK, SNDX, FTRE: Equity-to-Asset Comparison
For the Biotechnology subindustry, Tyra Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tyra Biosciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Tyra Biosciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Tyra Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tyra Biosciences (TYRA) has a Equity-to-Asset of 0.94 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tyra Biosciences and its competitors. This is near median its historical median of 0.95. According to the industry distribution chart, Tyra Biosciences ranks #116 out of 1416 companies in the Biotechnology industry, placing it in the top 8.2%.
Is Tyra Biosciences' Equity-to-Asset too high?
Tyra Biosciences' current Equity-to-Asset of 0.94 is near median its 10-year median of 0.95. The Biotechnology industry median Equity-to-Asset is 0.68. Tyra Biosciences' value of 0.94 is 38.2% above this industry median. Based on the distribution chart, Tyra Biosciences ranks #116 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Equity-to-Asset compare to STOK and SNDX?
According to the Biotechnology industry distribution chart, Tyra Biosciences ranks #116 out of 1416 companies for Equity-to-Asset. This places Tyra Biosciences in the top 8% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Tyra Biosciences' value of 0.94 is 38.2% above this benchmark. While the company's 10-year median is 0.95 vs. the industry median of 0.68, Tyra Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tyra Biosciences's current Equity-to-Asset of 0.94 is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tyra Biosciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tyra Biosciences's current Equity-to-Asset is 0.94, which is near median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Equity-to-Asset of 0.94. The current Equity-to-Asset is 0.94, which is near median its 10-year median of 0.95 and 38.2% above the Biotechnology industry median of 0.68. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Equity-to-Asset is 0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score
Get the complete analysis for TYRA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYRA has been successfully added to your 
